{"id":"W4381612727","doi":"10.1200/jco.22.01599","title":"Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Pembrolizumab; Ipilimumab; Medicine; Clinical endpoint; Internal medicine; Hazard ratio; Melanoma; Oncology; Clinical trial; Confidence interval; Cancer; Immunotherapy; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01135793,0.0008861856,0.002264017,0.0007480669,0.0008498163,0.001583938,0.0006468118,0.001483086,0.003102195],"category_scores_gemma":[0.005503516,0.0004140391,0.001898915,0.0006530909,0.0005765648,0.00119625,0.0007447493,0.003428677,0.001033463],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007574817,"about_ca_system_score_gemma":0.0008053155,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005593725,"about_ca_topic_score_gemma":0.0007962355,"domain_scores_codex":[0.9976981,0.001222922,0.0001795865,0.0002248969,0.0003197204,0.000354751],"domain_scores_gemma":[0.9960663,0.001093339,0.0008873845,0.000495246,0.0004520191,0.001005719],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.825912,0.008184638,0.0627059,0.0008514646,0.004043757,0.0003419841,0.0002437323,0.002271811,0.009740799,0.0003755328,0.00932872,0.07599968],"study_design_scores_gemma":[0.1644126,0.3452858,0.447426,0.0003255731,0.00864559,0.0007909582,0.0002168,0.003806404,0.01039009,0.001070851,0.01747718,0.0001521857],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9706404,0.008865718,0.001631244,0.0007474851,0.0003470438,0.001436358,0.008104116,0.0001079742,0.008119754],"genre_scores_gemma":[0.9774844,0.001354131,0.0005937419,0.001023726,0.0002503176,0.001041828,0.01469635,0.00003967097,0.003515835],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01135793,"threshold_uncertainty_score":0.06006724,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1069024919856014,"score_gpt":0.472260736291704,"score_spread":0.3653582443061026,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}